Literature DB >> 1621734

Guidelines for performing a pharmacoeconomic analysis.

L M Jolicoeur1, A J Jones-Grizzle, J G Boyer.   

Abstract

The fundamentals of pharmacoeconomics are presented. Pharmacoeconomic research is used to identify, measure, and compare the costs, risks, and benefits of programs, services, or therapies and determine which alternative produces the best health outcome for the resources invested. Each pharmacoeconomic method measures costs in monetary terms; the differences lie in the valuation of outcomes. In cost-minimization analysis, the outcomes are considered to be equal and therefore are not measured. Cost-benefit analysis measures outcomes in dollars, whereas cost-effectiveness analysis measures outcomes in nonmonetary units. In cost-utility analysis, outcomes expressed in nonmonetary units are adjusted for health-related quality of life. A well-designed pharmacoeconomic analysis involves 10 steps: (1) defining the problem, (2) determining the study's perspective, (3) determining the alternatives and outcomes, (4) selecting the appropriate pharmacoeconomic method, (5) placing monetary values on the outcomes, (6) identifying study resources, (7) establishing the probabilities of the outcomes, (8) applying decision analysis, (9) discounting costs or performing a sensitivity or incremental cost analysis, and (10) presenting the results, along with any limitations of the study. By adhering to the analytic steps described, the pharmacist undertaking a pharmacoeconomic evaluation has the greatest likelihood of obtaining valid and useful results.

Mesh:

Year:  1992        PMID: 1621734

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  23 in total

Review 1.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  A short term cost-effectiveness model for oral antidiabetic medicines in Europe.

Authors:  S C Hood; L Annemans; M Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

Review 3.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

4.  High technology drugs for cancer: the decision process for adding to a formulary.

Authors:  J L Glennie; D M Woloschuk; K W Hall
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 5.  Expanding the role of pharmacists in pharmacoeconomics: why and how?

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

6.  Impact of triplicate prescribing programme on psychotropic prescribing.

Authors:  A Bedikian; M A Gill
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

7.  Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.

Authors:  K E Agro; C A Bradley; N Mittmann; M Iskedjian; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

8.  Pharmacoeconomics and formulary decision making.

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 9.  The expanding role of pharmacy and therapeutics committees. The 1990s and beyond.

Authors:  W E Wade; W J Spruill; A T Taylor; R L Longe; D W Hawkins
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

10.  The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.

Authors:  K W Clarke; D Gray
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.